No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 12
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:26:23.243Z. Latest historical point 2024-08-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T16:26:23.243Z. Latest historical point 2026-03-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T16:26:23.243Z. Latest historical point 2024-08-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T16:26:23.243Z. Latest historical point 2024-08-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T16:26:23.243Z. Latest historical point 2024-08-14.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T16:26:23.243Z. Latest historical point 2026-03-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T16:26:23.243Z. Latest historical point 2024-08-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T16:26:23.243Z. Latest historical point 2024-08-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Contineum Therapeutics, Inc. (CTNM) stock was $12.60 as of Oct 6, 2026, 12:25 PM EDT, down 0.98% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +12.0%
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Biotechnology · San Diego, CA
Next Earnings Date
Oct 29, 2026
23 days away
EPS Estimate
-0.45
Revenue Est.
$5.65M
Last Quarter Results
EPS
$-0.40
vs Estimate
$-0.45
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CTNM | $473.84M | $12.60 | -0.98% | +12.01% | N/A | N/A | N/A |
| 2KMDA | $473.09M | $8.20 | +2.50% | +23.24% | +10.36% | +5.44% | vs CTNM |
| 3CERS | $474.59M | $2.35 | +0.64% | +48.76% | -17.30% | -9.37% | vs CTNM |
| 4DRUG | $469.98M | $48.02 | -3.55% | -6.49% | +6.76% | N/A | vs CTNM |
| 5ARVN | $479.07M | $7.42 | -0.47% | -22.28% | -38.16% | N/A | vs CTNM |
| 6SGHT | $467.38M | $8.59 | -3.70% | +169.84% | -18.69% | N/A | vs CTNM |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 7 analysts
Average Price Target
$22.43
+78.1% upside
Low
$17.00
Current
$12.60
High
$28.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.52 | $-0.46 | $-0.40 | 5 |
| Quarter ending Dec 2026 | $-0.51 | $-0.47 | $-0.42 | 5 |
| Quarter ending Mar 2027 | $-0.49 | $-0.49 | $-0.49 | 3 |
| Quarter ending Jun 2027 | $-0.50 | $-0.50 | $-0.50 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.77 | $-1.72 | $-1.62 | 5 |
| FY 2027 | $-2.23 | $-1.99 | $-1.73 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $5.65M | $5.65M | $5.65M | 2 |
| Quarter ending Dec 2026 | $7.50M | $7.50M | $7.50M | 6 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $4.29M | $4.29M | $4.29M | 4 |
| FY 2027 | $2.20M | $2.20M | $2.20M | 4 |
